tiprankstipranks
Trending News
More News >

Shanghai Fosun Pharmaceutical Announces Board Composition

Story Highlights
Shanghai Fosun Pharmaceutical Announces Board Composition

Don’t Miss TipRanks’ Half-Year Sale

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes 12 members with various roles such as executive, non-executive, and independent non-executive directors. This announcement highlights the company’s governance structure and the roles of each director in different board committees, which could impact the strategic direction and operational oversight of the company.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products, with a significant market presence in China.

Average Trading Volume: 7,025,116

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.06B

See more insights into 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1